ARTMS specializes in the physics, chemistry and materials science of cyclotron-produced radionuclides. Our core technology platform, the QUANTM Irradiation System™ (QIS™), is a complete cyclotron-based isotope production system designed to support high efficiency, large-scale and cost-effective production of commercially important medical isotopes such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu). QIS™ is used today by many of the major manufacturing networks to optimize production of a range of medical radioisotopes. ARTMS has been acquired by Telix Pharmaceuticals. Interested in joining the team? Search our open positions: https://telixpharma.com/careers/find-a-job/
| Website | http://www.artms.ca |
| Revenue | $6.3 million |
| Employees | 30 (20 on RocketReach) |
| Address | 8575 Commerce Crt, Burnaby, British Columbia V5A 4N5, CA |
| Industry | Pharmaceutical Manufacturing |
Looking for a particular ARTMS Inc employee's phone or email?
The ARTMS Inc annual revenue was $6.3 million in 2026.
Oddy Trillo is the Vice President Operations of ARTMS Inc.
20 people are employed at ARTMS Inc.
ARTMS Inc is based in Burnaby, British Columbia.